Drug Information

Drug (ID: DG01406) and It's Reported Resistant Information

• Name: Nivolumab
• Indication:
  In total 18 Indication(s)
  Central nervous system lymphoma [ICD-11: 2B33]; Approved; [1]
  Chronic myelogenous leukaemia [ICD-11: 2A20]; Approved; [1]
  Diffuse large B-cell lymphoma [ICD-11: 2A81]; Approved; [1]
  Esophageal cancer [ICD-11: 2B70]; Approved; [1]
  Follicular lymphoma [ICD-11: 2A80]; Approved; [1]
  Gastric adenocarcinoma [ICD-11: 2B72]; Approved; [1]
  Gastric adenocarcinoma [ICD-11: 2B72]; Approved; [1]
  Malignant pleural mesothelioma [ICD-11: 2C26]; Approved; [1]
  Melanoma [ICD-11: 2C30]; Approved; [1]
  Multiple myeloma [ICD-11: 2A83]; Approved; [1]
  Non-small-cell lung cancer [ICD-11: 2C25]; Approved; [1]
  Ovarian cancer [ICD-11: 2C73]; Approved; [1]
  Pancreatic cancer [ICD-11: 2C10]; Approved; [1]
  Prostate cancer [ICD-11: 2C82]; Approved; [1]
  Recurrent glioblastoma [ICD-11: 2A00]; Approved; [1]
  Renal cell carcinoma [ICD-11: 2C90]; Approved; [1]
  Small-cell lung cancer [ICD-11: 2C25]; Approved; [1]
  Triple negative breast cancer [ICD-11: 2C60-2C6Y]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (2 diseases)
  Melanoma [ICD-11: 2C30]; [2]
  Neuroendocrine carcinoma [ICD-11: 2D4Y]; [1]
• Target: Programmed cell death protein 1 (PD-1); PDCD1_HUMAN; [1]
• TTD Drug ID: D00GOV
• INTEDE ID: DR2826
• DrugBank ID: DB09035

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Brain cancer [ICD-11: 2A00]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Mismatch repair endonuclease PMS2 (PMS2) [3]

• Molecule Alteration: FS-deletion; p.K706fs*19 (c.2118delG)
• Sensitive Disease: FGFR-tacc positive glioblastoma [ICD-11: 2A00.01]
• Experimental Note: Identified from the Human Clinical Data

Melanoma [ICD-11: 2C30]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) [2]

• Molecule Alteration: Missense mutation; p.V600E (c.1799T>A)
• Resistant Disease: Melanoma [ICD-11: 2C30.0]
• Experimental Note: Identified from the Human Clinical Data

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) [2]

• Molecule Alteration: Missense mutation; p.V600K (c.1798_1799delGTinsAA)
• Sensitive Disease: Melanoma [ICD-11: 2C30.0]
• Experimental Note: Identified from the Human Clinical Data

Neuroendocrine carcinoma [ICD-11: 2D4Y]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Fibroblast growth factor receptor 3 (FGFR3) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Primary pulmonary lymphoepithelioma-like carcinoma [ICD-11: 2D4Y.Z]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: KB-3-1 cells; Lung; Homo sapiens (Human); CVCL_2088
• Mechanism Description: Pulmonary LELC with FGFR3 gene amplification may not respond well to nivolumab monotherapy. The combination of anlotinib and nivolumab can reverse the resistance to nivolumab in pulmonary LELC with FGFR3 gene amplification.

References

• Ref 1: Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification .Front Oncol. 2021 Oct 8;11:749682. doi: 10.3389/fonc.2021.749682. eCollection 2021. 10.3389/fonc.2021.749682
• Ref 2: Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant MelanomaClin Cancer Res. 2019 Feb 15;25(4):1272-1279. doi: 10.1158/1078-0432.CCR-18-1680. Epub 2019 Jan 10.
• Ref 3: Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair DeficiencyJ Clin Oncol. 2016 Jul 1;34(19):2206-11. doi: 10.1200/JCO.2016.66.6552. Epub 2016 Mar 21.